XML 19 R10.htm IDEA: XBRL DOCUMENT v3.20.2
Organization and principal activities
6 Months Ended
Jun. 30, 2020
Organization and principal activities  
Organization and Principal Activities

1.Organization and principal activities

Zai Lab Limited (the "Company") was incorporated on March 28, 2013 in the Cayman Islands as an exempted company with limited liability under the Companies Law of the Cayman Islands. The Company and its subsidiaries (collectively referred to as the "Group") are principally engaged in discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical needs in the China market and the global markets, including in the fields of oncology, infectious and autoimmune diseases.

The Group’s principal operations and geographic markets are in the People’s Republic of China ("PRC" or "China"). The accompanying consolidated financial statements include the financial statements of the Company and its subsidiaries.

As of June 30, 2020, the Group’s significant operating subsidiaries are as follows:

    

Place of

    

Date of

    

Percentage of

    

Name of company

incorporation

incorporation

ownership

Principal activities

Zai Lab (Hong Kong) Limited

 

Hong Kong S.A.R

April 29, 2013

 

100%

Operating company for business development and R&D activities and commercialisation of innovative medicines and device

Zai Lab (Shanghai) Co., Ltd.

 

PRC

January 6, 2014

 

100%

Development and commercialisation of innovative medicines and devices

Zai Lab (AUST) Pty., Ltd.

 

Australia

December 10, 2014

 

100%

Clinical trial activities

Zai Lab (Suzhou) Co., Ltd.

 

PRC

November 30, 2015

 

100%

Development and commercialisation of innovative medicines

Zai Biopharmaceutical (Suzhou) Co., Ltd.

 

PRC

June 15, 2017

 

100%

Development and commercialisation of innovative medicines

Zai Lab (US) LLC

 

U.S.

April 21, 2017

 

100%

Operating company for business development and R&D activities

Zai Lab International Trading (Shanghai) Co., Ltd.

 

PRC

November 6, 2019

 

100%

Commercialisation of innovative medicines and devices